Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Teva wins FDA approval for monthly schizophrenia injection Weltruza

9 October 2026 · By · Wire by Fusion42

Published

9 October 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at wtaq.com →

◆ Verified

Fusion42 · 10 October 2026 · Fusion42 review

Teva has received FDA approval for Weltruza, a monthly injectable treatment for adults with schizophrenia, utilizing Medincell's extended-release injectable technology, and expects to launch soon in the US.

This Wire brief sits within Fusion42's coverage of Biotech, and 14 sources have reported it between 9 Oct 2026 and 10 Oct 2026.

◆ ◆ The Wire takeaway

You can capitalise on the new US market for long-acting schizophrenia treatments as compliance improves with monthly injections. Teva's launch clears the way for competitors to explore extended-release formats in psychiatric drugs.

◆ Coverage

14 sources · first reported 9 Oct 2026 · latest 10 Oct 2026

◆ Topics

Biotechfda-approvalschizophrenialong-acting-injectionmedincellteva